Thalidomide in oral crohn’s disease refractory to conventional medical treatment

Journal of Pediatric Gastroenterology and Nutrition

Volumn 25, Issue 2, 1997, Pages 250-251

  Odeka, E B ^a   Miller, V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

CASE REPORT; CHILD; CHILDHOOD DISEASE; CORTICOSTEROID THERAPY; CROHN DISEASE; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CHILD; CROHN DISEASE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MOUTH DISEASES; THALIDOMIDE;

EID: 0030859308     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/00005176-199708000-00034     Document Type: Letter

References (3)

1. Odeka EB. Understanding Crohn's disease in children. Matern Child Health 1993;18:347-51.
2. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;2:1358.
3. Peterson PK, Hu S, Sheng WS, et al. Thalidomide inhibits tumor necrosis factor alpha production by lipopolysaccharide and lipoarabinomannam stimulated human microglial cells. J Infect Dis 1995;172:1137-40.